Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer

Launched by ALISON STOPECK · Jan 22, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at new ways to monitor how well chemotherapy is working for women with early stage breast cancer. Specifically, the study is comparing a special type of mammogram that uses a contrast agent—like a dye that helps images show more detail—with traditional breast MRI scans. The goal is to see if this new imaging method can better identify any remaining cancer after treatment, which can help doctors plan the best next steps for surgery. Participants will undergo 1-2 mammograms during their chemotherapy, and a small amount of contrast will be injected into a vein before the scans.

To be eligible for this trial, women aged 65 to 74 who have been diagnosed with locally advanced breast cancer can participate, provided they plan to receive at least 4 rounds of chemotherapy before surgery. However, women who are pregnant, have allergies to the contrast agent, have kidney issues, or diabetes cannot join the study. Participation may last up to 18 weeks, and during this time, the research team will collect information from medical records and leftover tissue from any biopsies or surgeries. This study could help improve how doctors assess treatment effectiveness in breast cancer patients.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Diagnosis with either type of invasive locally advanced breast cancer regardless of hormone receptor or Her2 status
• • Plan to receive at least 4 cycles of neoadjuvant chemotherapy ahead of definitive surgery
• Exclusion Criteria:
• • Pregnancy
• • Allergy/sensitivity to contrast agent
• • Decreased kidney function
• • Diabetes